Her-2neu Expression In Endometrial Carcinoma Patients- A Preliminary Study from Western India
A Preliminary Study from Western India
,
Abstract
Background: - Her-2neu is a gene from the epidermal growth factor receptor family. It is known to regulate cell growth. Her-2neu overexpression or amplification is more common in type2 endometrial cancer than in type1. Overexpression of Her-2neu has been associated with poor prognosis. This study aims to evaluate Her-2neu expression in endometrial carcinoma patients. Method: - 50 endometrial carcinoma patients were enrolled in the study. Her-2neu expression was studied by immunohistochemistry method on formalin fixed paraffin embedded tissue and correlated with clinical and pathological parameters as well as disease status. Result: - Her-2neu positivity was observed in 10% (5/50) of cases. Her-2neu expression was more frequent in postmenopausal women (10%). Her-2neu expression was more common in patientslymphovascular invasion (18%) and lymph node positivity (20%). A higher frequency of Her-2neu expression was seen in ER negative (22%), p53 mutant type (17%), WT1 positive (25%) and Vimentin positive (12%) tumors. In relation to disease free survival, Her-2neu positive tumors had a higher rate of relapse. Conclusion: - In the present study, higher expression of Her-2neu was observed in patients with lymphovascular invasion, lymph node positivity, ER negative, p53 mutant tumors, WT1 positive, Vimentin positive patients and those with reduce DFS (Disease Free Survival). The above findings suggest that Her-2neu to be associated with disease spread, its aggressiveness, proliferation in hormone-independent manner, its role in EMT (Epithelial-Mesenchymal Transition) process and negative prognostic implications.
1) Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC. Refining prognosis and REFERENCES 43 identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern pathology. 2015 Jun;28(6):836-44
2) Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic oncology research and practice. 2017 Dec;4:1-2.
3) Seshadri R. Clinical significate og HER2/neu oncogene amplification in primary breast cancer, The South Austrarian Breast Cancer Study Group. J clin Oncol. 1993;11:1736-42.
4) Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature reviews Molecular cell biology. 2001 Feb 1;2(2):127-37.
5) Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12.
6) Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, Backes F. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. Journal of Clinical Oncology. 2018 Jul 10;36(20):2044-51.
7) Brumm C, Riviere A, Wilckens C, Loening TH. Immunohistochemical investigation and Northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. VirchowsArchiv A. 1990 Nov;417:477-84.
8) Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erb B2) in endometrial cancers: correlation with overall survival. Cancer Research. 1995 Dec 1;55(23):5693-8.
9) Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell LG, Fowler JM. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. Journal of Clinical Oncology. 2006 May 20;24(15):2376-85.
10) Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology. 2013 Dec 1;26(12):1605-12.
11) Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2008 Jan 1;108(1):3-9.
12) Mori N, Kyo S, Nakamura M, Hashimoto M, Maida Y, Mizumoto Y, Takakura M, Ohno S, Kiyono T, Inoue M. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. British journal of cancer. 2010 Sep;103(6):889-98.
13) Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, Leelahakorn S, Pataradool K. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010 Jan 1;11(1):215-0.
14) Ross DS, Devereaux KA, Jin C, Lin DY, Zhang Y, Marra A, Makker V, Weigelt B, Ellenson LH, Chui MH. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. Modern Pathology. 2022 Jul 1;35(7):962-71.
15) Milde-Langosch K, Bamberger AM, Goemann C, Rössing E, Rieck G, Kelp B, Löning T. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. Journal of cancer research and clinical oncology. 2001 Sep;127:537-44.
16) Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid‐type endometrial carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997 Dec 15;80(12):2250-6.
17) Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 2005 Feb;24(9):1648-52.
18) Khillare CD, Khandeparkar SG, Joshi AR, Kulkarni MM, Gogate BP, Battin S. Immunohistochemical expression of vimentin in invasive breast carcinoma and its correlation with clinicopathological parameters. Nigerian Medical Journal. 2019 Jan 1;60(1):17-21.
2) Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic oncology research and practice. 2017 Dec;4:1-2.
3) Seshadri R. Clinical significate og HER2/neu oncogene amplification in primary breast cancer, The South Austrarian Breast Cancer Study Group. J clin Oncol. 1993;11:1736-42.
4) Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature reviews Molecular cell biology. 2001 Feb 1;2(2):127-37.
5) Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12.
6) Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, Backes F. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. Journal of Clinical Oncology. 2018 Jul 10;36(20):2044-51.
7) Brumm C, Riviere A, Wilckens C, Loening TH. Immunohistochemical investigation and Northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. VirchowsArchiv A. 1990 Nov;417:477-84.
8) Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erb B2) in endometrial cancers: correlation with overall survival. Cancer Research. 1995 Dec 1;55(23):5693-8.
9) Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell LG, Fowler JM. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. Journal of Clinical Oncology. 2006 May 20;24(15):2376-85.
10) Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology. 2013 Dec 1;26(12):1605-12.
11) Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2008 Jan 1;108(1):3-9.
12) Mori N, Kyo S, Nakamura M, Hashimoto M, Maida Y, Mizumoto Y, Takakura M, Ohno S, Kiyono T, Inoue M. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. British journal of cancer. 2010 Sep;103(6):889-98.
13) Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, Leelahakorn S, Pataradool K. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010 Jan 1;11(1):215-0.
14) Ross DS, Devereaux KA, Jin C, Lin DY, Zhang Y, Marra A, Makker V, Weigelt B, Ellenson LH, Chui MH. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. Modern Pathology. 2022 Jul 1;35(7):962-71.
15) Milde-Langosch K, Bamberger AM, Goemann C, Rössing E, Rieck G, Kelp B, Löning T. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. Journal of cancer research and clinical oncology. 2001 Sep;127:537-44.
16) Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid‐type endometrial carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997 Dec 15;80(12):2250-6.
17) Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 2005 Feb;24(9):1648-52.
18) Khillare CD, Khandeparkar SG, Joshi AR, Kulkarni MM, Gogate BP, Battin S. Immunohistochemical expression of vimentin in invasive breast carcinoma and its correlation with clinicopathological parameters. Nigerian Medical Journal. 2019 Jan 1;60(1):17-21.
| Files | ||
| Issue | Vol 16 No 2 (2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/bccr.v16i2.19441 | |
| Keywords | ||
| Endometrial carcinoma Her-2neu Immunohistochemistry | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Dixit D, Rajvik K, Patel N, Vora H. Her-2neu Expression In Endometrial Carcinoma Patients- A Preliminary Study from Western India. Basic Clin Cancer Res. 2025;16(2):111-118.
